Looking forward to the trends that will define the new year, and predictions for 2023, a group of leading life sciences industry analysts predicted a much more cautious approach to investment, a reflection of larger macroeconomic challenges, yet continued long-term investment in an asset class that continues to grow in importance. “We’ve entered a really slow, kind of cautious period,” JLL Head of Americas Work Dynamics and Industry Research Amber Schiada said. “We’ve also seen valuations come back down to earth, too.” The contours of 2023 were set, in large part, by the recent past. In the nine-year bull run from 2014 to 2021, which Alexandria Real Estate Equities Chairman Joel Marcus called “unprecedented," the biotech industry saw roughly 500 IPOs and $300B in venture capital raised. Marcus said it’s clear the market is healthy, but investors are more careful about deploying capital today, which will have a significant impact on the next 12 months of funding, competition and real estate development. “It’s good and bad news,” Marcus said. “It’s good news for the companies that succeed, with positive data and bad news for the companies that won't be able to raise money, and need to look at shutting down or combining or something like that.” Here are some of the trends and predictions nine industry analysts and experts believe will shape the market to come. A Buyer’s Market For Space With the funding market becoming more cautious and development pipelines poised to deliver new product, especially in major markets, this year may become more of a buyer's, or renter's, market. Unispace Head of Life Sciences Dean Poillucci sees inventory outstripping demand during this period, leading… Read Full Story | 
